Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma, especially since there is a 20% response rate. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.